Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty

Division of Cardiology B, Hopital Cardiologique, Lille, France. bertrandme@AOL.com

OBJECTIVES: This study sought to determine whether pravastatin affects clinical or angiographic restenosis after coronary balloon angioplasty. BACKGROUND: Experimental data and preliminary clinical studies suggest that lipid-lowering drugs might have a beneficial effect on restenosis after coronary angioplasty. METHODS: In a multicenter, randomized, double-blind trial, 695 patients were randomized to receive pravastatin (40 mg/day) or placebo for 6 months after successful balloon angioplasty. All patients received aspirin (100 mg/day). The primary angiographic end point was minimal lumen diameter (MLD) at follow-up, assessed by quantitative coronary angiography. A sample size of 313 patients per group was required to demonstrate a difference of 0.13 mm in MLD between groups (allowing for a two-tailed alpha error of 0.05 and a beta error of 0.20). To allow for incomplete angiographic follow-up (estimated lost to follow-up rate of 10%), 690 randomized patients were required. Secondary end points were angiographic restenosis rate (restenosis assessed as a categoric variable, > 50% stenosis) and clinical events (death, myocardial infarction, target vessel revascularization). RESULTS: At baseline, clinical, demographic, angiographic and lipid variables did not differ significantly between groups. In patients treated with pravastatin, there was a significant reduction in total and low density lipoprotein cholesterol and triglyceride levels and a significant increase in high density lipoprotein cholesterol levels. At follow-up the MLD (mean +/- SD) was 1.47 +/- 0.62 mm in the placebo group and 1.54 +/- 0.66 mm in the pravastatin group (p = 0.21). Similarly, late loss and net gain did not differ significantly between groups. The restenosis rate (recurrence > 50% stenosis) was 43.8% in the placebo group and 39.2% in the pravastatin group (p = 0.26). Clinical restenosis did not differ significantly between groups. CONCLUSIONS: Although pravastatin has documented efficacy in reducing clinical events and angiographic disease progression in patients with coronary atherosclerosis, this study shows that it has no effect on angiographic outcome at the target site 6 months after coronary angioplasty.

This article has been cited by other articles:

				H. Kamishirado, T. Inoue, M. Sakuma, T. Tsuda, T. Hayashi, K. Takayanagi, and K. Node Effects of Statins on Restenosis After Coronary Stent Implantation Angiology, February 1, 2007; 58(1): 55 - 60. [Abstract] [PDF]

				W. A. Jaber, R. J. Lennon, V. Mathew, D. R. Holmes Jr, A. Lerman, and C. S. Rihal Application of Evidence-Based Medical Therapy Is Associated With Improved Outcomes After Percutaneous Coronary Intervention and Is a Valid Quality Indicator J. Am. Coll. Cardiol., October 18, 2005; 46(8): 1473 - 1478. [Abstract] [Full Text] [PDF]

				T. E Delea, T. A Jacobson, P. W. Serruys, J. S Edelsberg, and G. Oster Cost-Effectiveness of Fluvastatin Following Successful First Percutaneous Coronary Intervention Ann. Pharmacother., April 1, 2005; 39(4): 610 - 616. [Abstract] [Full Text] [PDF]

				K. Toutouzas, A. Colombo, and C. Stefanadis Inflammation and restenosis after percutaneous coronary interventions Eur. Heart J., October 1, 2004; 25(19): 1679 - 1687. [Abstract] [Full Text] [PDF]

				F Niroomand, O Hauer, C P Tiefenbacher, H A Katus, and W Kuebler Influence of alcohol consumption on restenosis rate after percutaneous transluminal coronary angioplasty and stent implantation Heart, October 1, 2004; 90(10): 1189 - 1193. [Abstract] [Full Text] [PDF]

				T. J. Wilt, H. E. Bloomfield, R. MacDonald, D. Nelson, I. Rutks, M. Ho, G. Larsen, A. McCall, S. Pineros, and A. Sales Effectiveness of Statin Therapy in Adults With Coronary Heart Disease Arch Intern Med, July 12, 2004; 164(13): 1427 - 1436. [Abstract] [Full Text] [PDF]

				P. D. Thompson, P. Clarkson, and R. H. Karas Statin-Associated Myopathy JAMA, April 2, 2003; 289(13): 1681 - 1690. [Abstract] [Full Text] [PDF]

				A. Farb, M. John, E. Acampado, F. D. Kolodgie, M. F. Prescott, and R. Virmani Oral Everolimus Inhibits In-Stent Neointimal Growth Circulation, October 29, 2002; 106(18): 2379 - 2384. [Abstract] [Full Text] [PDF]

				G. Theilmeier, R. Quarck, P. Verhamme, M.-L. Bochaton-Piallat, M. Lox, H. Bernar, S. Janssens, M. Kockx, G. Gabbiani, D. Collen, et al. Hypercholesterolemia impairs vascular remodelling after porcine coronary angioplasty Cardiovasc Res, August 1, 2002; 55(2): 385 - 395. [Abstract] [Full Text] [PDF]

				P. W. J. C. Serruys, P. de Feyter, C. Macaya, N. Kokott, J. Puel, M. Vrolix, A. Branzi, M. C. Bertolami, G. Jackson, B. Strauss, et al. Fluvastatin for Prevention of Cardiac Events Following Successful First Percutaneous Coronary Intervention: A Randomized Controlled Trial JAMA, June 26, 2002; 287(24): 3215 - 3222. [Abstract] [Full Text] [PDF]

				W. Palinski and S. Tsimikas Immunomodulatory Effects of Statins: Mechanisms and Potential Impact on Arteriosclerosis J. Am. Soc. Nephrol., June 1, 2002; 13(6): 1673 - 1681. [Abstract] [Full Text] [PDF]

				H J G H Mulder, M J Schalij, B Kauer, R F Visser, P R M van Dijkman, J W Jukema, A H Zwinderman, and A V G Bruschke Pravastatin and endothelium dependent vasomotion after coronary angioplasty: the PREFACE trial Heart, November 1, 2001; 86(5): 533 - 539. [Abstract] [Full Text] [PDF]

				J. B. Braunstein, A. Cheng, G. Cohn, M. Aggarwal, C. M. Nass, and R. S. Blumenthal Lipid Disorders : Justification of Methods and Goals of Treatment Chest, September 1, 2001; 120(3): 979 - 988. [Abstract] [Full Text] [PDF]

				S. Bandyopadhyay, A.J. Bayer, and M.S. O'Mahony Age and gender bias in statin trials QJM, March 1, 2001; 94(3): 127 - 132. [Abstract] [Full Text] [PDF]

				C. Indolfi, A. Cioppa, E. Stabile, E. Di Lorenzo, G. Esposito, A. Pisani, A. Leccia, L. Cavuto, A. M. Stingone, A. Chieffo, et al. Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury J. Am. Coll. Cardiol., January 1, 2000; 35(1): 214 - 221. [Abstract] [Full Text] [PDF]

				A. Corsini Reviews: Fluvastatin: Effects Beyond Cholesterol Lowering Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(3): 161 - 175. [Abstract] [PDF]

				J. C. LaRosa, J. He, and S. Vupputuri Effect of Statins on Risk of Coronary Disease: A Meta-analysis of Randomized Controlled Trials JAMA, December 22, 1999; 282(24): 2340 - 2346. [Abstract] [Full Text] [PDF]

				P.J. de Feyter Editorials: Lipids and coronary restenosis: an elusive link Eur. Heart J., October 1, 1999; 20(19): 1371 - 1374. [PDF]

				A. Kleemann, S. Eckert, A. von Eckardstein, W. Lepper, U. Schernikau, U. Gleichmann, P. Hanrath, E. Fleck, A. Neiss, S. Kerber, et al. Effects of lovastatin on progression of non-dilated and dilated coronary segments and on restenosis in patients after PTCA. The Cholesterol Lowering Atherosclerosis PTCA Trial (CLAPT) Eur. Heart J., October 1, 1999; 20(19): 1393 - 1406. [Abstract] [PDF]

				B Jorgensen, S Simonsen, K Endresen, K Forfang, T Egeland, A.T Hostmark, and E Thaulow Luminal loss and restenosis after coronary angioplasty. The role of lipoproteins and lipids Eur. Heart J., October 1, 1999; 20(19): 1407 - 1414. [Abstract] [PDF]

				G. C. Flaker, J. W. Warnica, F. M. Sacks, L. A. Moye, B. R. Davis, J. L. Rouleau, R. R. Webel, M. A. Pfeffer, E. Braunwald, and for the Cholesterol and Recurrent Events CARE Inve Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations J. Am. Coll. Cardiol., July 1, 1999; 34(1): 106 - 112. [Abstract] [Full Text] [PDF]

				O. Johansen, M. Brekke, I. Seljeflot, M. Abdelnoor, and H. Arnesen n-3 fatty acids do not prevent restenosis after coronary angioplasty: results from the CART study J. Am. Coll. Cardiol., May 1, 1999; 33(6): 1619 - 1626. [Abstract] [Full Text] [PDF]

				P.W. Serruys, D.P. Foley, G. Jackson, H. Bonnier, C. Macaya, M. Vrolix, A. Branzi, J. Shepherd, H. Suryapranata, P.J. de Feyter, et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty: Final results of the fluvastatin angiographic restenosis (FLARE) trial Eur. Heart J., January 1, 1999; 20(1): 58 - 69. [Abstract] [PDF]

				A. W. Chan, D. L. Bhatt, D. P. Chew, M. J. Quinn, D. J. Moliterno, E. J. Topol, and S. G. Ellis Early and Sustained Survival Benefit Associated With Statin Therapy at the Time of Percutaneous Coronary Intervention Circulation, February 12, 2002; 105(6): 691 - 696. [Abstract] [Full Text] [PDF]